Topic Archives: bempedoic acid

[Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and more recent comments here.] Picture the gurbling fumaroles of Yellowstone: from the late 1990’s and on into […]

Comments

  • Bempedoic acid was approved by the FDA in February. The comments suggesting that LDL-C has nothing to do with heart di...

  • Blanco's projection for Esperion (ESPR) may have been overblown, but 2020 should be a pivotal year for the company as th...

  • Bempedoic acid is a significant advance. Why? Because it can be used in patients who can't tolerate statins because of m...

  • Esperion has worked hard to get bempedoic acid & the ezetimibe-bempedoic combo to the point where the FDA green light is...

  • $ESPR small position > Esperion Announces Late-Breaking Oral Presentation of Final Results of Phase 3 Long-Term Safety S...

  • #ESPR 2 in moderation Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Long-Term Safety Study of Bemp...

  • $ESPR > Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Long-Term Safety Study of Bempedoic Acid ht...

  • A Seeking Alpha article points out that there are a number of clinical-stage biotechs facing upcoming catalysts. Among t...

  • Bempedoic acid can be sole solution, but FDA wanted long term CVOT trial. Esperion plans to submit a New Drug Applicatio...

  • Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid — Study 4 Met Primary...

  • $ESPR other in MODERATION Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Ac...

  • $ESPR sp - (long no link) Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Aci...

  • $ESPR - Upcoming Milestones March 2018: Top-line results expected from the pivotal Phase 3 Study 4 (10...

  • $ESPR - Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Fourth Quarter and Full Year 201...

  • $ESPR, long:- Some thoughts about $ESPR versus "MDCO's inclisiran" as as stated by Citicorp in Pascal's post: In the ...

  • $ESPR re: today's 10%+ share price decline (ouch) three possible culprits . 1) sharp pullback from a fairly torrid rise...

  • Yahoo: Citi Downgrades Esperion As Hope Of Acquisition Dwindles Benzinga Elizabeth Balboa BenzingaJanuary 22, 2018 ...

  • $ESPR LONG ll.com: Esperion downgraded to Neutral from Buy at Citi Citi analyst Joel Beatty downgraded Esperion Th...

  • $Chip12. To help fill out the Catalyst Calendar, below are additional 2018 Catalysts from the FDA Calendar of some sto...

  • $ESPR LONG Esperion Therapeutics upgrade details -- to Strong Buy at Needham; tgt raised to $81 (57.13) Needham ...

  • $ESPR LONG Esperion Therapeutics (ESPR 60.66) target raised to $75 from $20 at Chardan Capital Markets. Firm notes ...

  • $ESPR LONG Reports Q3 (Sep) loss of $1.86 per share, $0.09 worse than the Capital IQ Consensus of ($1.77). The bem...

  • $ESPR, getting all their ducks in a row. 2018 looks to be a very interesting year for them with 5 phase 3 trials report...

  • $ESPR - October 17,17 Investor and analyst day: http://investor.esperion.com//eventdetail.cfm?eventid=185577 Agenda ...

  • $ESPR long - Esperion Completes Patient Enrollment in Global Pivotal Phase 3 Program for Bempedoic Acid http://investo...

  • $ESPR (of high relevance) NEJM EDITORIAL "Targeting Inflammation in Coronary Artery Disease" Robert A. Harrington, ...

  • $ESPR "Bempedoic acid combinations show promise for LDL lowering" Healo Inc. September 16, 2017 A phase 2 study ...

  • $ESPR $PCSK9i $SNY Doc, Esperion also wins on pricing, right? Bempedoic Acid + ezetimibe With or w/o low-dose st...

  • it would be fascinating to do a kind of isobolographic waterfall curve here---not trying to confuse people, but for a fi...

  • $ESPR - Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Second Quarter 2017 Financial Re...

  • $ESPR - Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus A...

  • $ESPR np Esperion Announces Positive Top-Line Results From Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Plus...

  • Over a year ago, we presented a new lipid mgmt company to you called Gemphire ($GEMP). We were deeply skeptical and felt...

  • $ESPR - Esperion to Provide Bempedoic Acid Franchise Development Program Updates and Second Quarter Financial Results h...

  • Hi: thanks for posting and asking. As regards Esperion, we still love the company, and it is one of multiple moving targ...

  • Rick, thanks for posting this article. I am astonished that recurrent adverse reactions are this low. I believe that $ES...

  • $ESPR Here is a summary and opinion from the NEJM journal watch: MEDICAL NEWS | PHYSICIAN'S FIRST WATCH July 25, ...

  • $ESPR - Esperion Announces Initiation of Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor http://investor.e...

  • $ESPR long since mid-2015. This stock is an object lesson for all Dr. KSS's followers. To wit: after falling like the pr...

  • $MRK Thanks for your comments on the hottest biotech news today. If I understand correctly Doc, to promote anacetrapib, ...

  • I think that's a much much better move, seriously. I am hearing some rumors now that Merck may not even pursue anacetrap...

  • $ESPR - Esperion Announces FDA Confirmation of Regulatory Pathway to Approval for the Combination of Bempedoic Acid and ...

  • But---and not meaning to come across as argumentative or picking nits---one of the main points here is that statin intol...

  • Glenn, tempest in a teapot really. Fewer than 10,000 Americans have been prescribed PCSK9is because the kind of familial...

  • Which reminds me: at the last conference call, I did make an error. I alluded to $ESPR having a market cap of $3B, and t...

  • Good article with ESPR CEO Tim Mayleben setting the record straight (The Facts About Bempedoic Acid) http://www.esper...

  • $ESPR fp Esperion's Tim Mayleben sets the record straight on "The Facts About Bempedoic Acid." http://www.esperion.c...

  • $ESPR was never a full member of PhRMA, was always an associate or second-tier member. Being excluded doesn't influence ...

  • $ESPR np - Esperion Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2017 Financial Results h...

  • $ESPR: UBS upgrade #Esperion, PT=$52 (3/30) A Clear Approval Path on LDL-Lowering; Transition of Coverage; Upgra...

  • $ESPR, long. The problem is "they" do not time stamp the new properly. The 1/2 hearted upgrade was out after the cl...

  • $ESPR: Hi Doc and all, I looked at Esperion's call options long and hard today. The premiums were extremely rich for ...

  • $ESPR - Esperion Announces FDA Confirmation Regarding Regulatory Pathway to Approval for an LDL-C Lowering Indication fo...

  • $ESPR: A good article on bempedoic acid for Gummies who are relatively new to Esperion: https://www.ncbi.nlm.nih.g...

  • $ESPR: Basically, all the arguments in the articles I read today (NEJM, Forbes, IBD et all.) were alluded to in my fir...

  • $ESPR -Waiting for Dr KSS to weigh in may not be wise. As recently as March 4th, he restated his views which have been ...

  • $ESPR http://www.investors.com/news/technology/esperion-dive-on-amgen-heart-study-counter-intuitive-on-pricing/ Esper...

  • $ESPR long. Np $AMGN. Thanks bbtech. Reading all of these synopses leaves me very confused: 1. I never fully grasped w...

  • I'm not a Doctor, nor especially Dr. KSS, but for those like me who watched the $ESPR, long now, train roll away for a t...

  • $ESPR New Forbes article on this subject, just in: "Amgen drug prevents heart attacks, not deaths, disappointing e...

  • I think that the results should be helpful, not hurtful to ESPR. Lowering LDL works. Bempedoic Acid is oral. If there ar...

  • $ESPR's annual shareholder meeting will be live and online 17 April 2017 at 8 am. Would be good if 2-3 of this group ...

  • $ESPR: Provides Bempedoic Acid Development Program Update; Reports Fourth Quarter and Full Year 2016 Results. http://in...

  • $ESPR long: Up again nearly 12% today. My feeling is that this is reflating at least partly because of the political cli...

  • $ESPR long Arthur Toga, PhD, head of the brain imaging and mapping center at USC, Professor of Neurology, Ophthalmolo...

  • We've kvetched forever about $ESPR's undervaluation, but today's action really does surprise. I sense something more is ...

  • Scorp: As you know, for me it is a foregone conclusion, based on what's already known, that bemp (bempedoic acid) will s...

  • $ESPR: A CVOT assessing bempedoic acid started a month ago. According to ClinicalTrials.gov, the estimated final data co...

  • $ESPR np - Esperion Completes Enrollment of Pivotal Phase 3 Long-Term Safety and Tolerability Study of Bempedoic Acid in...

  • $ESPR np - Esperion Announces Initiation of Global Cardiovascular Outcomes Trial for Bempedoic Acid http://investor.esp...

  • $ESPR np - Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid Global Phase 3 Program To...

  • One hopes that, based on this interesting new study, bempedoic acid may have another avenue in which to shine: that of s...

  • Definitely true as things now stand, but also up in the air because Robert Califf's tenure is uncertain. We feel that Ca...

  • "A possible shift in policy at the FDA means that a much heralded novel new cholesterol drug won’t reach the US market...

  • I'm not huge on Califf and some of his seeming "gacha" decisions, but I suspect that every director has had issues, as w...

  • $ESPR np - Probably goes to moderation DOC. Esperion Therapeutics Announces Publication of Definitive Paper on Bemped...

  • $ESPR Abstract: Esperion Therapeutics is developing bempedoic acid to treat cardiovascular disease and to help those t...

  • $ESPR Esperion – Another overhang removed Esperion (ESPR) reported yet another data set that showed its drug, bemped...

  • $ESPR np - Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports Third Quarter 2016 Financi...

  • I definitely suspect statins intensify Parkinson's disease. Though bempedoic acid could do the same, as statins are fing...

  • $ESPR - Bempedoic Acid Global Phase 3 Clinical Program to Include Patients on Any Statin at Any Dose 1002-035 Study M...

  • $ESPR (long): Wondering about #6 – Expecting good news from a company when news is delayed. In a press release 04Aug,...

  • While the agreement between $AMGN and $ARWR may bolster $ARWR a little, I would add here, and recall I closed out my $AM...

  • something to keep an eye on regarding PCKS9 inhibitors and Bempedoic acid and ESPR. http://www.internalmedicinenews.com/...

  • Two thoughts regarding Commandment #1: I saw a little discourse between Alan and Ben about posting quarterly/annual rep...

  • I believe that eventually, bempedoic acid will be first line lipid therapy in doctor offices, and that the LDL hypothesi...

  • $ESPR http://www.esperion.com/note-from-our-ceo/ This is Tim Mayleben – CEO of Esperion Therapeutics with some tho...

  • $ESPR http://www.forbes.com/sites/matthewherper/2016/06/29/can-esperion-therapeutics-ever-regain-wall-streets-trust/#...

  • Anshuman: it's because Califf and Eric Topol are friends and both have an attitude that statin intolerance is rare and t...

  • I need to read the paper...thanks for providing the reference! I doubt statins affect the process under discussion, but ...

  • Tyler: you raise a good point, and I am charmed by your inquisitiveness. While I can see how this avenue would be appeal...

  • As an investment, $ESPR has been the girlfriend who pours out her love for you and then rescinds it, and you stay in the...

  • I ALWAYS leave out stocks when I do that list from memory. Darn. Long ARTH. Grade A HN score. I trust mgmt and think ...

  • The failure of Lilly's CETPi paves the way for unparalleled success with ATP citrate lyase inhibitor bempedoic acid from...

  • $ESPR- Esperion Therapeutics Provides Bempedoic Acid Development Program Updates; Reports First Quarter 2016 Financial R...

  • HN, you can bet that beloranib, if approved someday, will be fairly expensive. Plus, it's currently subcutaneous inject...

  • Scorpio...long both ESPR and ZFGN...IMO the fat loss from belanorib and lack of bad side effects will be the main reason...

  • Re $ESPR and bempedoic acid, what about $ZFGN's beloranib? It looks like it also reduces LDL cholesterol, plus you lose...

  • Should've reread ZKSS' Feb 21 piece on Esperion and Merck's CETPi before posting. http://www.stockgumshoe.com/2016/02/s...

  • We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies.

    More Info